On January 6, 2019 Enzychem Lifesciences, a leading global biopharmaceutical company focusing on innovative new drug development for unmet medical needs, reported that it will present at Biotech Showcase 2020, to be held January 13–15, 2020, during the most important week in healthcare at the Hilton San Francisco Union Square (Press release, Enzychem Lifesciences, JAN 6, 2020, View Source [SID1234552759]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Chief Medical Officer, Dr. Myung Hwan Kim will present at Biotech Showcase as follows:

Date: Tuesday, January 14, 2020
Time: 3:30 PM
Room: Franciscan A (Ballroom Level)
Location: Hilton San Francisco Union Square Hotel, 333 O’Farrell Street, San Francisco, CA

Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and executives in one place during the course of one of the industry’s largest annual healthcare investor conferences, J.P. Morgan Annual Healthcare Conference.

On January 06, 2020 Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, reported that its corporate name change from "Atossa Genetics Inc." to "Atossa Therapeutics, Inc." became effective at 12:01 a.m. ET today, January 6, 2020 (Press release, Atossa Genetics, JAN 6, 2020, View Source;utm_medium=twitter [SID1234629125]). The Company’s common stock will continue to trade on the NasdaqCM exchange under the ticker symbol "ATOS."

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Over the last several years, we have transitioned the Company’s focus on developing therapies to treat breast cancer, breast density and other breast conditions," said Steve Quay, Ph.D., M.D., president and CEO of Atossa. "Changing our name to Atossa Therapeutics, Inc. more clearly reflects our focus on developing therapies and continues to honor Princess Atossa, the great queen of the Achaemenid Empire, who reigned in the fifth century BCE and who is the earliest recorded woman with breast cancer. She is featured in the The Emperor of All Maladies: A Biography of Cancer, the Pulitzer Prize-winning book by Siddhartha Mukherjee on the history of cancer."

On January 6, 2020 Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL) therapeutic platform, reported that its chief executive officer, Dr. Gerrit Dispersyn, will present at Biotech Showcase 2020 on Monday, January 13, 2020 at 2:00 pm Pacific Time at the Hilton San Francisco Union Square (Press release, Phio Pharmaceuticals, JAN 6, 2020, View Source [SID1234552706]). Phio will also be hosting institutional investor and partnering meetings at the LifeSci Advisors Corporate Access Event being held at the Sir Francis Drake Hotel in San Francisco from January 13-15, 2020.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the presentation at Biotech Showcase, Dr. Dispersyn will discuss Phio’s proprietary gene-silencing technology INTASYLTM and provide updates on its broad early-stage pipeline applying INTASYL both as a standalone therapy and in combination with adoptive cell-therapy. This will include updates on the Company’s lead product candidates PH-762, designed to silence PD-1 receptor expression on T cells, and PH-804, designed to silence expression of TIGIT on T cells and NK cells.

Details of the presentation are as follows:

Date:

Monday, January 13, 2020

Time:

2:00 p.m. (PST)

Track:

Yosemite C (Ballroom Level)

Location:

Hilton San Francisco Union Square

A live audio webcast of the presentation will be made available on the Events section of the Company’s website at View Source with a replay accessible following the live presentation.

On January 6, 2020 Relay Therapeutics, a new breed of company at the intersection of computation and biotechnology, reported that Sanjiv Patel, M.D., president and chief executive officer, will present an overview of the company’s business and scientific objectives at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 13th at 12:00 p.m. PT (3:00 p.m. ET) (Press release, Relay Therapeutics, JAN 6, 2020, View Source [SID1234552743]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On January 6, 2019 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) reported that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will participate in the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020 at 7:30 am PT, or 10:30 am ET, in San Francisco, California (Press release, BioMarin, JAN 6, 2020, View Source [SID1234552760]). To access the live webcast, please visit the investor section of the BioMarin website, www.biomarin.com. A replay will also be archived on the site for at least one week following the event.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!